Demographics of Study Subjects
| . | Long-Term Survivors . | Progressors . |
|---|---|---|
| No. of subjects | 21 | 21 |
| Years of age (mean ± SD) | 43 ± 6 | 44 ± 9 |
| Range of age | 36-58 | 30-65 |
| Race | 17 Whites | 20 Whites |
| 2 African Americans | 1 African American | |
| 1 Asian | ||
| 1 Hispanic | ||
| Gender (male/female) | 19/2 | 21/0 |
| Year of probable infection (mean year ± SD) | 1981 ± 2 yr | 1982 ± 2 yr |
| Year tested seropositive (mean year ± SD) | 1985 ± 1 yr | 1986 ± 2 yr |
| Symptoms | 21 Asymptomatic | 8 Kaposi’s Sarcoma |
| 5Pneumocystis carinii pneumonia | ||
| 2 Thrush | ||
| 2 Hairy leukoplakia | ||
| 2 Night sweats | ||
| 1 Mycobacterium aviumcomplex | ||
| 2 Toxoplasmosis | ||
| 1 Neuropathy | ||
| 2 Chronic diarrhea | ||
| 2 Low-grade fever | ||
| 21 Absolute CD4+ cell count <200 cells/μL | ||
| Antiretroviral medication | 21 None | 6 None 12 3′-azido-3-de oxythymidine |
| 4 2′,3′dideoxyino sine | ||
| 3 2′,3′ dideoxycyti dine | ||
| 6 2′,3′ didehydro- 3′-deoxythymi dine |
| . | Long-Term Survivors . | Progressors . |
|---|---|---|
| No. of subjects | 21 | 21 |
| Years of age (mean ± SD) | 43 ± 6 | 44 ± 9 |
| Range of age | 36-58 | 30-65 |
| Race | 17 Whites | 20 Whites |
| 2 African Americans | 1 African American | |
| 1 Asian | ||
| 1 Hispanic | ||
| Gender (male/female) | 19/2 | 21/0 |
| Year of probable infection (mean year ± SD) | 1981 ± 2 yr | 1982 ± 2 yr |
| Year tested seropositive (mean year ± SD) | 1985 ± 1 yr | 1986 ± 2 yr |
| Symptoms | 21 Asymptomatic | 8 Kaposi’s Sarcoma |
| 5Pneumocystis carinii pneumonia | ||
| 2 Thrush | ||
| 2 Hairy leukoplakia | ||
| 2 Night sweats | ||
| 1 Mycobacterium aviumcomplex | ||
| 2 Toxoplasmosis | ||
| 1 Neuropathy | ||
| 2 Chronic diarrhea | ||
| 2 Low-grade fever | ||
| 21 Absolute CD4+ cell count <200 cells/μL | ||
| Antiretroviral medication | 21 None | 6 None 12 3′-azido-3-de oxythymidine |
| 4 2′,3′dideoxyino sine | ||
| 3 2′,3′ dideoxycyti dine | ||
| 6 2′,3′ didehydro- 3′-deoxythymi dine |